Clinical Trials

AI in Drug Discovery Strategic Intelligence Research Report 2024: Healthcare, Macroeconomic, Technology, and Regulatory Trends Impacts

Dec 20 2024 09:49

Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: AI in drug discovery" report has been added to ResearchAndMarkets.com's offering.

This report consolidates the latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the AI in drug discovery, as well as providing insights into the leading players and future disruptors across the value chain, and providing insights into key drugs and markets from the analyst's Pharma Intelligence Center.

In recent years, the pharma industry has been taken over by a wave of digital transformation, leading to the integration of advanced technologies across different aspects of the pharma value chain.

Artificial intelligence (AI) and big data are at the forefront of driving innovation, from enhancing drug discovery to optimizing clinical trial design.
The drug discovery process is a very expensive and time-consuming process. Despite recent technological advancements, the success rate of research and development (R&D) is very low, adding emphasis to the need for innovative technologies, such as AI, to improve efficiency and outcomes.

Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future for AI.

Scope

  • A dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the AI-driven drug discovery landscape. This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the AI in drug discovery market.

Reasons to Buy

  • Understand the key trends accelerating or hindering the AI in drug discovery space.
  • See market forecasts for different therapies within AI up to 2028.
  • Understand recent and influential developments in AI.
  • Review of leaders and disruptors across the AI value chain.

Key Topics Covered:

  • Players
  • Thematic Briefing
  • Trends
  • Industry Analysis
  • Value Chain
  • Companies
  • Drug Development Scorecard
  • Abbreviations

A selection of companies mentioned in this report includes, but is not limited to:

  • Alphabet
  • Amazon
  • Dassault Systemes
  • IBM
  • Cisco
  • Informatica
  • Oracle
  • Microsoft
  • BenevolentAI
  • Exscientia
  • Recursion
  • IQVIA
  • Insilico Medicine
  • Syneos Health
  • Parexel
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Eli Lilly and Co
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • Merck & Co

For more information about this report visit https://www.researchandmarkets.com/r/o8zx81

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 


Subscribe to global regulatory updates

We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.